Biohybrid Solutions™ is pioneering a new approach to bioconjugate production using polymer-based protein engineering. This innovation allows more control, expands the available polymer library, and minimizes the issues inherent with attaching polyethylene glycol (PEG) to proteins. Polymer-based protein engineering achieves the same outcomes as the more common molecular biology-dependent approach of classic protein engineering.
As Biohybrid Solutions™ co-founder and CEO Alan Russell, Ph.D., says, “Polymer-based protein engineering provides another option to scientists seeking to overcome the challenges of current PEGylation technology.”
PEGylation, which decorates the surface of protein with PEG, typically reduces a protein’s immunogenicity, extends a protein’s time in the body, and can improve its solubility. PEGylation, however, is not an easily controlled reaction. “You essentially place PEG and proteins together and hope for the best,” Dr. Russell explains. “There are few levers available to control and fine-tune the reaction.” Although PEGylation is notoriously difficult to commercialize, there are 10 FDA-approved protein-PEG conjugates currently marketed in the United States…
Read the full article from GEN published on October 1, 2016
More Company News
Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer
Myris Therapeutics emerges from stealth to announce new name and strategic focus Proprietary polymer chemistry enables ultra-high drug to antibody ratios of 50 - 100 and new chemical space for precision targeted ADC payloads PITTSBURGH, Feb. 20,...
BioHybrid Solutions Holdings, Inc. Announces Expansion of its Drug Development Leadership
Pittsburgh, PA. June 02, 2023 Biohybrid Solutions Holdings, Inc. (BHS), is a biotechnology company using advanced polymer technologies to address outstanding challenges in the development of biologic drugs. BHS’ NanoArmor® technology balances...
BioHybrid Solutions Holdings, Inc. Appoints Mark Murcko as Board Member
Pittsburgh, PA. August 09, 2022 We are excited to announce the appointment of Mark Murcko, Ph.D., as our newest Board Member. Mark brings over three decades of industry experience, having been at the center of many transformational biotech efforts...